Xia Liu

List of Publications by Year
in descending order

19 papers	662 citations	567281 15 h-index	752698 20 g-index
20 all docs	20 docs citations	20 times ranked	1056 citing authors

#	Article	IF	Citations
1	Expression analysis of histone acetyltransferases in rice under drought stress. Biochemical and Biophysical Research Communications, 2014, 443, 400-405.	2.1	88
2	Wnt3a: functions and implications in cancer. Chinese Journal of Cancer, 2015, 34, 554-62.	4.9	72
3	Upregulation of NEK2 is associated with drug resistance in ovarian cancer. Oncology Reports, 2014, 31, 745-754.	2.6	62
4	Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3β signaling. Scientific Reports, 2017, 7, 41656.	3.3	58
5	Tumor suppressor genes associated with drug resistance in ovarian cancer (Review). Oncology Reports, 2013, 30, 3-10.	2.6	50
6	Oncogenes associated with drug resistance in ovarian cancer. Journal of Cancer Research and Clinical Oncology, 2015, 141, 381-395.	2.5	41
7	Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer. Oncology Reports, 2017, 37, 3084-3092.	2.6	35
8	Discovery of microarray-identified genes associated with ovarian cancer progression. International Journal of Oncology, 2015, 46, 2467-2478.	3.3	34
9	Microarray-based identification of genes associated with cancer progression and prognosis in hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2016, 35, 127.	8.6	33
10	Upregulation of E2F transcription factor 3 is associated with poor prognosis in hepatocellular carcinoma. Oncology Reports, 2014, 31, 1139-1146.	2.6	30
11	Microarray‐based identification of genes associated with prognosis and drug resistance in ovarian cancer. Journal of Cellular Biochemistry, 2019, 120, 6057-6070.	2.6	26
12	Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer. Oncology Reports, 2014, 32, 362-372.	2.6	22
13	Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer. International Journal of Oncology, 2016, 48, 243-252.	3.3	21
14	Associations of tumor suppressor SPARCL1 with cancer progression and prognosis. Oncology Letters, 2017, 14, 2603-2610.	1.8	21
15	Downregulation of NEK11 is associated with drug resistance in ovarian cancer. International Journal of Oncology, 2014, 45, 1266-1274.	3.3	20
16	NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer. Journal of Cellular Biochemistry, 2020, 121, 4470-4483.	2.6	16
17	Low expression of KCNN3 may affect drug resistance in ovarian cancer. Molecular Medicine Reports, 2018, 18, 1377-1386.	2.4	13
18	Big Data-Based Identification of Multi-Gene Prognostic Signatures in Liver Cancer. Frontiers in Oncology, 2020, 10, 847.	2.8	10

#	Article	IF	Citations
19	Low Expression of SLC7A11 Confers Drug Resistance and Worse Survival in Ovarian Cancer via Inhibition of Cell Autophagy as a Competing Endogenous RNA. Frontiers in Oncology, 2021, 11, 744940.	2.8	9